QHP Capital completes $1.1bn continuation fund for Azurity Pharmaceuticals
Thursday, March 19, 2026 · first reported by PE Hub and 1 other
QHP Capital has achieved a $1.1bn final close for a single-asset continuation vehicle backing portfolio company Azurity Pharmaceuticals, with support from secondaries investors HarbourVest and Pantheon. The continuation fund enables QHP to extend its investment horizon in the pharmaceutical portfolio business.
- Firm
- QHP Capital
- Also named
- HarbourVest Partners, Pantheon Ventures
- Fund
- Azurity Pharmaceuticals continuation fund
- Size
- $1.1B
- Stage
- Final close
- Asset class
- Secondaries, Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
2 sourcesMore in Secondaries & GP stakes
From the same day- Ares leads €300m Europastry continuation fundPrivate Equity Wire +2
- BNP Paribas AM Alts seals $722m infra secondaries fund close, is already planning successor raiseAltAssets
- BNPP AM Alts raises $722m for debut infrastructure secondaries fundIPE Real Assets
- Fremman Capital raises oversubscribed continuation fund for UK nursery operator Kids PlanetAltAssets
- HighVista Strategies taps Raudel Yanez as managing director and PE secondaries headPE Hub
- Revelation adds to secondaries teamAlternatives Watch